

# Piero Pileri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9596735/publications.pdf>

Version: 2024-02-01

40  
papers

4,650  
citations

393982

19  
h-index

580395

25  
g-index

46  
all docs

46  
docs citations

46  
times ranked

4925  
citing authors

#	ARTICLE	IF	CITATIONS
1	Binding of Hepatitis C Virus to CD81. , 1998, 282, 938-941.		1,814
2	Antigen-independent activation of naive and memory resting T cells by a cytokine combination.. Journal of Experimental Medicine, 1994, 180, 1159-1164.	4.2	521
3	A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1759-1763.	3.3	338
4	Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C.. Journal of Experimental Medicine, 1993, 178, 17-25.	4.2	246
5	Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine, 2010, 28, 6367-6373.	1.7	208
6	Human Monoclonal Antibodies That Inhibit Binding of Hepatitis C Virus E2 Protein to CD81 and Recognize Conserved Conformational Epitopes. Journal of Virology, 2000, 74, 10407-10416.	1.5	192
7	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell, 2021, 184, 1821-1835.e16.	13.5	180
8	Association of hepatitis C virus envelope proteins with exosomes. European Journal of Immunology, 2004, 34, 2834-2842.	1.6	178
9	Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infection and Immunity, 1990, 58, 1308-1315.	1.0	126
10	Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature, 2021, 600, 530-535.	13.7	124
11	Synthesis and Characterization of a Native, Oligomeric Form of Recombinant Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein. Journal of Virology, 2004, 78, 10328-10335.	1.5	117
12	Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.. Journal of Experimental Medicine, 1990, 172, 861-868.	4.2	98
13	Helicobacter pylori-specific CD4+ T-cell clones from peripheral blood and gastric biopsies. Infection and Immunity, 1995, 63, 1102-1106.	1.0	90
14	Angiopoietin-like 7, a novel pro-angiogenic factor over-expressed in cancer. Angiogenesis, 2014, 17, 881-896.	3.7	55
15	Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer. Journal of Controlled Release, 2018, 280, 76-86.	4.8	47
16	Immunostimulation by a partially modified retro-inverso-tuftsin analog containing Thr1.sum..psi.[NHCO](R,S)Lys2 modification. Journal of Medicinal Chemistry, 1991, 34, 3372-3379.	2.9	43
17	T cell receptor Î³Î´ repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen-reactive Î³Î´ clones. European Journal of Immunology, 1995, 25, 355-363.	1.6	40
18	The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor. Virus Research, 2001, 80, 1-10.	1.1	35

#	ARTICLE	IF	CITATIONS
19	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120976119.	3.3	27
20	FAT1: a potential target for monoclonal antibody therapy in colon cancer. British Journal of Cancer, 2016, 115, 40-51.	2.9	25
21	Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting. Journal of Experimental and Clinical Cancer Research, 2015, 34, 103.	3.5	20
22	ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer. Oncotarget, 2016, 7, 63596-63610.	0.8	20
23	Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. Nature Communications, 2022, 13, .	5.8	20
24	A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins. Journal of Proteomics, 2011, 75, 532-547.	1.2	11
25	Antibodies, epicenter of SARS-CoV-2 immunology. Cell Death and Differentiation, 2021, 28, 821-824.	5.0	9
26	TCTN2: a novel tumor marker with oncogenic properties. Oncotarget, 2017, 8, 95256-95269.	0.8	9
27	Abstract B7: Angiopoietin like 7, a novel pro-angiogenetic factor over-expressed in cancer.. , 2013, , .		1
28	Abstract 5533: Novel targets and monoclonal antibodies for cancer therapy.. , 2013, , .		1
29	Abstract C165: Discovery of a lectin-like receptor family protein as a novel target for monoclonal antibody therapy.. , 2013, , .		1
30	Abstract 5579: Novel proteins highly expressed in tumor identified by a high throughput immunoproteomic approach. , 2010, , .		0
31	Abstract C96: A novel polyclonal antibody library for expression profiling of poorly characterized membrane and secreted human proteins.. , 2011, , .		0
32	Abstract B180: Novel candidate tumor markers identified by a high-throughput immunoproteomics approach.. , 2011, , .		0
33	Abstract 2857: Monoclonal antibodies against novel tumor markers for cancer diagnosis and treatment .. , 2013, , .		0
34	Abstract C190: A novel monoclonal antibody for colon cancer therapy.. , 2013, , .		0
35	Abstract 1769: A novel potential cancer marker and therapeutic target. , 2014, , .		0
36	Abstract 4622: Discovery of a novel target for monoclonal antibody therapy of breast and ovary cancers. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 3575: Novel targets and monoclonal antibodies for antibody-drug conjugate therapy. , 2015, , .		0
38	Abstract 4384A: A novel potential therapeutic target for breast, lung, ovary and colon cancer. , 2015, , .		0
39	Abstract 4870: A novel potential target for cancer immunotherapy. , 2016, , .		0
40	Abstract 3800: Novel targets and monoclonal antibodies for cancer therapy. , 2016, , .		0